Purpose: We evaluated the clinical outcomes of castration resistant prostate cancer (CRPC) patients treated with Docetaxel in Taichung Veterans General Hospital.

Materials and Methods: From Dec 2004 to Feb 2015, 208 patients with castration resistant prostate cancer were treated with Docetaxel70-75mg/m2, IV, every three to four weeks or 50mg/m2, every two weeks. The PSA response, time to progression duration, overall survival and adverse events wereanalyzed.

Results: The median age of the 208 patients was 69 years (range 44–86) and the median PSA when started Docetaxel was 47 ng/ml (range 2.24–4761). The median treatment courses of the patients were 6 (range 1–44). PSA response was found in 105patients (50.5%). Twenty-eight patients (13.5%) had the phenomenon of PSA flare up. The median progression free survival was 5 months (range 0–54) and the median overall survival was 13 months (range 0–80). The most common subjective adverse effects were neutropenia. About one-third patients (35%) had grade3–4 neutropenia

Conclusion: Good PSA response and fair survival outcome were demonstrated in CRPC patients treated with docetaxel. However, high risk of neutropenia should be kept in mind.

Back to Top

Document information

Published on 31/08/16

Licence: Other

Document Score

0

Views 10
Recommendations 0

Share this document

claim authorship

Are you one of the authors of this document?